J Xiang

Summary

Affiliation: University of Saskatchewan
Country: Canada

Publications

  1. ncbi A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells
    Jim Xiang
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Immunol 174:7497-505. 2005
  2. pmc Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Sakatoon, Saskatchewan, Canada
    Immunology 120:90-102. 2007
  3. ncbi Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity
    Tianpei He
    Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 4:105-11. 2007
  4. ncbi Antigen specificity acquisition of adoptive CD4+ regulatory T cells via acquired peptide-MHC class I complexes
    Siguo Hao
    Department of Oncology, Research Unit, Saskatchewan Cancer Agency, College of Medicine, Saskatoon, Saskatchewan, Canada
    J Immunol 181:2428-37. 2008
  5. ncbi Mapping protein: carbohydrate interactions
    Gerald F Audette
    Department of Medical Microbiology and Immunology, University of Alberta, 1 15 Medical Sciences Building, Edmonton, AB, T6G 2H7, Canada
    Curr Protein Pept Sci 4:11-20. 2003
  6. ncbi Molecular and immunophenotypical characterization of progressive and regressive leukemia cell lines
    Siguo Hao
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 20:290-9. 2005
  7. ncbi Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1
    J Xiang
    Department of Microbiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    J Interferon Cytokine Res 20:349-54. 2000
  8. ncbi Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes
    S Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    Exp Oncol 28:126-31. 2006
  9. ncbi Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells
    J Xiang
    Departments of Microbiology and Pathology, Saskatoon Cancer Center, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, S7N 4H4, Saskatchewan, Canada
    Leuk Res 25:909-15. 2001
  10. ncbi Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor
    C M Cairns
    Department of Microbiology, Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada
    J Immunol 167:57-65. 2001

Collaborators

  • F Li
  • X Zhang
  • Z Chen
  • Anurag Saxena
  • H Huang
  • Y Chen
  • J R Gordon
  • Y Xie
  • S Ahmed
  • S Xu
  • Wei Li
  • Deming Sun
  • Z Xing
  • J Xu
  • C Zheng
  • Q Wu
  • K Li
  • J Yang
  • J Yuan
  • Q Liu
  • K Bonham
  • Z Jia
  • H Yu
  • Ross M Kedl
  • Hui Shao
  • Deborah H Anderson
  • Siguo Hao
  • Zhenmin Ye
  • Meiqing Shi
  • Yongqing Liu
  • Terence Moyana
  • Tianpei He
  • Khawaja Ashfaque Ahmed
  • Dajing Xia
  • T Chan
  • Tim Chan
  • Yangdou Wei
  • Xulin Guo
  • Liping Su
  • Manjunatha Ankathatti Munegowda
  • S Sas
  • Xiaochu Wu
  • Chaoke Tang
  • XiaoHua Wang
  • Z Ye
  • Weidong Zhang
  • S Hao
  • Ou Bai
  • Channakeshava Sokke Umeshappa
  • Yulin Deng
  • M Dean Chamberlain
  • A El-Gayed
  • A Sami
  • Jiang Zhong
  • M Qureshi
  • Yong Peng
  • Xuguang Bi
  • Mabood Qureshi
  • Gerald F Audette
  • C M Cairns
  • Sean J Mulligan
  • Jennifer C Oberg
  • Manju Ankathatti Munegowda
  • Qinghe Meng
  • Andrea D Hawrysh
  • Kristy M James
  • Rajni Chibbar
  • Junqiong Huang
  • Suzanne Laferte
  • Keshav Sokke Umeshappa
  • Sam Zong
  • M Shi
  • Bei Zhang
  • Sylvia Van Den Hurk
  • Q Meng
  • Ping Zhang
  • Henry J Kaplan
  • Amer Sami
  • X Guo
  • Yan Ke
  • Ali El-Gayed
  • Sigou Hao
  • Mabood Quereshi
  • Weifeng Dong
  • Yuhong He
  • Xuquang Bi
  • Xuling Guo
  • Svein Carlsen
  • Li Zong
  • Bernie Juurlink

Detail Information

Publications85

  1. ncbi A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells
    Jim Xiang
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Immunol 174:7497-505. 2005
    ..These results have substantial implications for research in antitumor and other aspects of immunity...
  2. pmc Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Sakatoon, Saskatchewan, Canada
    Immunology 120:90-102. 2007
    ..In addition, mDC(EXO) could also more efficiently eradicate established tumours. Therefore, mature DC pulsed with EXO may represent a new, highly effective DC-based vaccine for the induction of antitumour immunity...
  3. ncbi Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity
    Tianpei He
    Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 4:105-11. 2007
    ..Therefore, IFN-gamma-activated immortal DC2.4 cells may prove to be useful in the study of DC biology and antitumor immunity...
  4. ncbi Antigen specificity acquisition of adoptive CD4+ regulatory T cells via acquired peptide-MHC class I complexes
    Siguo Hao
    Department of Oncology, Research Unit, Saskatchewan Cancer Agency, College of Medicine, Saskatoon, Saskatchewan, Canada
    J Immunol 181:2428-37. 2008
    ..Taken together, the Ag-specificity acquisition of CD4(+) Tr cells via acquiring DC's pMHC I may be an important mean in augmenting CD4(+) Tr cell suppression...
  5. ncbi Mapping protein: carbohydrate interactions
    Gerald F Audette
    Department of Medical Microbiology and Immunology, University of Alberta, 1 15 Medical Sciences Building, Edmonton, AB, T6G 2H7, Canada
    Curr Protein Pept Sci 4:11-20. 2003
    ..Here, we review these developments, and examine the strengths, weaknesses, and pitfalls of these methods...
  6. ncbi Molecular and immunophenotypical characterization of progressive and regressive leukemia cell lines
    Siguo Hao
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 20:290-9. 2005
    ..In conclusion, our results contribute further information in the understanding of the molecular mechanisms associated with the regression and progression of P815 and P198 tumor cells...
  7. ncbi Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1
    J Xiang
    Department of Microbiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    J Interferon Cytokine Res 20:349-54. 2000
    ..A better understanding of the mechanisms by which tumor cells modulate the host immune system may result in newer approaches for manipulating host-tumor interactions that favor the development of a protective antitumor immune response...
  8. ncbi Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes
    S Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    Exp Oncol 28:126-31. 2006
    ..To investigate potential role of highly metastatic BL6-10 tumor cell-released exosomes (EXO) in transfer of metastatic activity into poorly metastatic tumor cell line F1...
  9. ncbi Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells
    J Xiang
    Departments of Microbiology and Pathology, Saskatoon Cancer Center, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, S7N 4H4, Saskatchewan, Canada
    Leuk Res 25:909-15. 2001
    ..This study thus highlights the potential utility of IL-18 as an antitumor agent, a role that it can fulfil alone or in combination with other immunomodulatory cytokines such as IL-12...
  10. ncbi Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor
    C M Cairns
    Department of Microbiology, Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada
    J Immunol 167:57-65. 2001
    ..Thus, lymphotactin has natural adjuvant activities that may augment antitumor responses via effects on both T cells and neutrophils and thereby could be important in gene transfer immunotherapies for some cancers...
  11. doi Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice
    S Sas
    Division of Oncology, Cancer Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Gene Ther 15:655-66. 2008
    ..Therefore, vaccination of fiber-modified adenovirus-transfected DCs to enhance expression of tumor antigens such as HER-2/neu is likely representative of a new direction in DC-based vaccine of breast cancer...
  12. ncbi DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy
    Z Chen
    Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W0, Canada
    Cell Immunol 214:60-71. 2001
    ..Taken together, our data clearly underscore the critical nature of employing DCs of full maturity for DC-based antitumor vaccination strategies...
  13. ncbi Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy
    H Huang
    Department of Oncology, Research Unit, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    Gene Ther 12:999-1010. 2005
    ..This novel therapeutic strategy with enhancement of Tc1 tumor localization in the therapy of well-established tumors may become a tool of considerable conceptual interest in the implementation of future clinical objectives...
  14. ncbi Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells
    Z Chen
    Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada
    Int J Cancer 93:539-48. 2001
    ..Therefore, DCs that had phagocytosed apoptotic/necrotic tumor cells appear to offer new strategies in DC cancer vaccines...
  15. doi Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity
    J Xiang
    Cancer Research Unit, Saskatchewan Cancer Agency, Departments of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Gene Ther 16:430-8. 2009
    ..Therefore, AdV(TERT)mTNF-alpha gene therapy may be very useful in the immunotherapy of cancer...
  16. ncbi Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors
    Z Ye
    Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    Cancer Gene Ther 14:661-75. 2007
    ..Therefore, CD8+ T cells engineered to secrete TNF-alpha may be useful when designing strategies for adoptive T-cell therapy of solid tumors...
  17. ncbi Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 3:205-11. 2006
    ..Therefore, DC-derived EXO may represent a more effective EXO-based vaccine in induction of antitumor immunity...
  18. ncbi Cancer gene therapy by adenovirus-mediated gene transfer
    Q Wu
    Adenovirus Group, Veterinary Infectious Disease Organization, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada
    Curr Gene Ther 1:101-22. 2001
    ..We also discuss the current limitations of the adenoviral vector system and how they may be circumvented in future developments relating to targeted gene delivery...
  19. ncbi Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis
    T Chan
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Gene Ther 14:409-20. 2007
    ..These results may have an important impact in designing DC-based antitumor vaccines...
  20. ncbi HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination
    T Chan
    Cancer Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4
    Gene Ther 13:1391-402. 2006
    ..Therefore, DCs genetically engineered to express tumor antigens such as HER-2/neu represent a new direction in DC vaccine of breast cancer...
  21. ncbi CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion
    Dajing Xia
    Research Unit, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    J Immunol 177:2976-84. 2006
    ..These principles could be applied to not only antitumor immunity, but also other immune disorders (e.g., autoimmunity)...
  22. ncbi CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses
    Channakeshava Sokke Umeshappa
    Research Unit, Research Division, Saskatchewan Cancer Agency and Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Immunol 182:193-206. 2009
    ..Therefore, our findings may have great impacts in not only the antitumor immunity, but also the regulatory T cell-dependent immune tolerance in vivo...
  23. doi Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes
    Zhenmin Ye
    Research Unit, Departments of Oncology and Immunology, Saskatchewan Cancer Agency, College of Medicine, University of Saskatchewan, Saskatoon, Sask, Canada
    Autoimmunity 41:501-11. 2008
    ..Therefore, the above elucidated principles for CD4+ Th cells will have substantial implications in autoimmunity and antitumor immunity, and regulatory T-cell-dependent immune suppression...
  24. doi Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
    Y Chen
    Cancer Research Unit, Research Division, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    Cancer Gene Ther 18:489-99. 2011
    ....
  25. ncbi Cloning and expression of functional cDNA genes of a mouse/human chimeric antibody rcM4
    M Boyd
    Saskatoon Cancer Center, Department of Microbiology, University of Saskatchewan, Canada
    Tumori 80:473-9. 1994
    ..They thus have potential utility in the construction of some novel hybrid proteins such as those containing both antitumor immunoglobulins and cytokine molecules for use in cancer immunotherapy...
  26. doi Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity
    Yufeng Xie
    Division of Health Research, Saskatchewan Cancer Agency, Saskatchewan, Saskatoon, Canada
    J Immunol 185:5268-78. 2010
    ..Therefore, our data indicate that Ag-specific CD8(+) T cells can modulate immune responses via T cell-released EXOs, and T cell EXOs may be useful for treatment of autoimmune diseases...
  27. doi Acquired pMHC I complexes greatly enhance CD4(+) Th cell's stimulatory effect on CD8(+) T cell-mediated diabetes in transgenic RIP-mOVA mice
    Khawaja Ashfaque Ahmed
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    Cell Mol Immunol 5:407-15. 2008
    ..This study thus expands the current knowledge in T cell-mediated autoimmunity and provides insight into the nature of CD4(+) T cell-mediated help in CD8(+) CTL induction...
  28. ncbi Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses
    Y Xie
    1 Cancer Research Unit, Research Division, Departments of Oncology, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada 2 Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
    Cancer Gene Ther 20:590-8. 2013
    ..Therefore, the engineered DCHER2/neu-P30 vaccine may provide a new immunotherapy alternative for women with HER2/neu(+) breast cancer, especially for trastuzumab-resistant HER2/neu(+) breast cancer patients. ..
  29. ncbi Production and characterization of a tumor-specific monoclonal antibody ACT19 recognizing an epitope distinctive from sialosyl-Tn on the TAG72 antigen
    J Xiang
    Department of Microbiology, University of Saskatchewan, Saskatoon, Canada
    Tumori 79:58-65. 1993
    ..CONCLUSIONS: The ACT19 antibody appears to be a useful marker for colon and stomach cancers, and this additional anti-TAG72 antibody may be useful in conjunction with the B72.3 antibody in pathology and clinical application...
  30. ncbi Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors
    Hui Huang
    Research Unit, Saskatchewan Cancer Agency, Department of Microbiology, University of Saskatchewan, Saskatoon, Canada
    Int J Cancer 109:817-25. 2004
    ....
  31. pmc Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses
    Siguo Hao
    Department of Oncology and Immunology, Division of Health Research, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Immunol 179:2731-40. 2007
    ..Therefore, EXO-targeted active CD4+ T cell vaccine may represent a novel and highly effective vaccine strategy for inducing immune responses against not only tumors, but also other infectious diseases...
  32. pmc CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes
    Hui Huang
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Immunology 120:148-59. 2007
    ..Taken together, these results will have important implications for designing adoptive T-cell immunotherapy protocols in treatment of solid tumors...
  33. doi LFA-1 defect-induced effector/memory CD8+ T cell apoptosis is mediated via Bcl-2/Caspase pathways and associated with downregulation of CD27 and IL-15R
    Zhenmin Ye
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon S7N 4H4, Canada
    Mol Immunol 47:2411-21. 2010
    ..Therefore, our study provides important evidence on and elucidates the molecular mechanism associated with the role LFA-1 signaling plays in effector and memory CD8(+) T cell survival...
  34. ncbi Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    J Leukoc Biol 82:829-38. 2007
    ..Therefore, the EXO(OVA)-uptaken CD4(+) T cells may represent a new, effective, EXO-based vaccine strategy in induction of immune responses against tumors and other infectious diseases...
  35. ncbi IL-10 has a distinct immunoregulatory effect on naive and active T cell subsets
    Zhenmin Ye
    Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    J Interferon Cytokine Res 27:1031-8. 2007
    ..The anergic CD4(+) T cells suppress T cell proliferation mainly through a CTLA-4-mediated pathway. The distinct role of IL-10 on T cell subsets may be useful in designing T cell-based immunotherapy of cancer and infectious diseases...
  36. ncbi Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation
    Zhenmin Ye
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 4:277-85. 2007
    ....
  37. ncbi Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses
    Yongqing Liu
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Res 65:4955-62. 2005
    ..Taken together, our findings provide an important insight into immunologic alterations in progressive and regressive tumors and an implication for dendritic cell-based approaches in the design of cancer vaccines...
  38. ncbi CD4(+) T cells stimulate memory CD8(+) T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion
    Meiqing Shi
    Saskatchewan Cancer Agency, Department of Microbiology and Immunology, College of Medicine, University of Saskatchewan, 20 Campus Dr, Saskatoon S7N 4H4, Canada
    J Leukoc Biol 80:1354-63. 2006
    ..These results highlight a previously undescribed role of active CD4(+) T cells in triggering expansion of memory CD8(+) T cells...
  39. doi Defect of CD8+ memory T cells developed in absence of IL-12 priming for secondary expansion
    Zhenmin Ye
    Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cell Mol Immunol 5:147-52. 2008
    ..However, IL-12 signaling is not involved in CD8+ Tm cell survival and recall responses. Therefore, this study provides useful information for vaccine design and development...
  40. pmc Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha
    Weidong Zhang
    Department of Oncology, Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 0W0
    Immunology 108:177-88. 2003
    ..Thus, DCs engineered to secrete TNF-alpha may offer a new strategy in DC cancer vaccines...
  41. ncbi Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression
    Hui Huang
    Research Unit, Saskatchewan Cancer Agency, Departments of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 4H4 Canada
    Cancer Res 62:2043-51. 2002
    ..Taken together, our data provide solid evidence of a potent synergy between adoptive CD4+ and CD8+ T-cell therapy and Lptn gene transfer into tumor tissues, which culminated in the eradication of well-established tumor masses...
  42. ncbi Increased susceptibility of tumorigenicity and decreased anti-tumor effect of DC vaccination in aged mice are potentially associated with increased number of NK1.1+CD3+ NKT cells
    Meiqing Shi
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon S7N 4H4, Canada
    Exp Oncol 27:125-9. 2005
    ..It is established that aging leads to declines in immune function. However, the mechanisms underlying remain poorly understood...
  43. ncbi Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors
    Hui Huang
    Research Unit, Saskatchewan Cancer Agency, Department of Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 4H4
    Cell Immunol 217:12-22. 2002
    ..Taken together, our data provide solid evidence of a potent synergy between adoptive T-cell therapy and IP-10 gene transfer into tumor tissues, which culminated in the eradication of well-established tumor masses...
  44. doi T cell precursor frequency differentially affects CTL responses under different immune conditions
    Zhenmin Ye
    Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, Saskatchewan, Canada
    Biochem Biophys Res Commun 367:427-34. 2008
    ..Taken together, these findings may have important implications for optimizing immunotherapy against cancer...
  45. ncbi Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity
    Yongqing Liu
    Research Unit, Saskatchewan Cancer Agency and Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W0, Canada
    Cancer Gene Ther 9:202-8. 2002
    ..Thus, DCs engineered to express CD40L by adenovirus-mediated CD40 ligand gene transfer may offer a new strategy in production of DC cancer vaccines...
  46. ncbi Analysis of the gene expression profiles of immature versus mature bone marrow-derived dendritic cells using DNA arrays
    Zhuang Chen
    Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, Saskatchewan, S7N 4H4, Canada
    Biochem Biophys Res Commun 290:66-72. 2002
    ..g., IGF-1, MMP-13, STRAP) not reported previously in these cells...
  47. ncbi Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase
    Meiqing Shi
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, 20 Campus Drive, Saskatoon, Sask, Canada S7N 4H4
    Biochem Biophys Res Commun 360:702-7. 2007
    ....
  48. ncbi CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity
    Xueshu Zhang
    Department of Oncology, University of Saskatchewan, Saskatoon, Canada
    J Immunol 175:2931-7. 2005
    ..Taken together, CD4-8- DCs stimulate development of IL-10-secreting CD4+ Tr1 cells that mediated immune suppression, whereas both CD4+8- and CD4-8+ DCs effectively primed animals for protective CD8+ CTL-mediated antitumor immunity...
  49. doi Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses
    Yufeng Xie
    Research Unit, Saskatchewan Cancer Agency, Departments of Oncology, Pathology, and Biology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Res 69:7756-66. 2009
    ..Therefore, our study may have great impact in designing a combined radiation therapy with immunotherapy of cancer...
  50. ncbi Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin
    H Huang
    Department of Microbiology, College of Medicine, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W0, Canada
    Biochem Biophys Res Commun 281:378-82. 2001
    ..These data suggest that Lptn could potentially be an important protein in the regulation of T and B lymphocytes and neutrophil trafficking, and thereby also their roles in inflammatory and immunological responses...
  51. ncbi A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells
    Siguo Hao
    Department of Oncology, Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Exp Oncol 27:56-60. 2005
    ..The work was aimed on investigation of the effect of implantation of microencapsulates on tumor growth in vivo...
  52. ncbi Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity
    Yongqing Liu
    Departments of Microbiology and Pathology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 0W0
    J Gene Med 5:668-80. 2003
    ..Tumor antigen presentation by dendritic cells (DCs) to T cells in lymphoid organs is crucial for induction of antitumor immune responses. Fms-like tyrosine kinase 3 ligand (Flt3L) is a regulator of hematopoietic cell development...
  53. doi CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones
    Xueshu Zhang
    Cancer Research Unit, Saskatchewan Cancer Agency and Departments of Oncology and Immunology, Pathology, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 0W0, Canada
    Biochem Biophys Res Commun 379:954-8. 2009
    ..Therefore, our data provide new information for and may thus have useful impacts in CD40 ligation-based immunotherapy of cancer...
  54. ncbi CD4+ T cell acquisition of the bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II and costimulatory CD40, CD54, CD80, OX40L, and 41BBL
    Tianpei He
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 4H4
    Biochem Biophys Res Commun 362:822-8. 2007
    ..These results provide some useful information in composition and dynamics of immunological synapses...
  55. ncbi Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor
    Meiqing Shi
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Tumori 91:531-8. 2005
    ..In the present study, we investigated the antitumor immunity derived from vaccination of fusion hybrids between DCs and engineered J558/IL-12 myeloma cells secreting Th1 cytokine IL-12...
  56. ncbi Conversion of tolerogenic CD4-8- dendritic cells to immunogenic ones inducing efficient antitumor immunity
    Xueshu Zhang
    Department of Oncology, University of Saskatchewan, Saskatchewan, Canada
    Cancer Biother Radiopharm 21:74-80. 2006
    ..Therefore, our results may have a significant impact in designing DC-based antitumor vaccines...
  57. ncbi CD4+ T cell-independent maintenance and expansion of memory CD8+ T cells derived from in vitro dendritic cell activation
    Meiqing Shi
    Research Unit, Saskatchewan Cancer Agency, Department of Microbiology and Immunology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Canada S7N 4H4
    Int Immunol 18:887-95. 2006
    ..Collectively, these findings demonstrate that in contrast to acute infections, maintenance and expansion of CD8+ Tm cells after priming with OVA protein-pulsed dendritic cells are independent of CD4+ T cells...
  58. ncbi Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity
    Yongqing Liu
    Research Unit, Departments of Oncology and Pathology, College of Medicine, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4
    Leuk Res 26:757-63. 2002
    ....
  59. ncbi Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity
    Dajing Xia
    Research Unit, Saskatchewan Cancer Agency, Departments of Oncology, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cancer Biother Radiopharm 19:322-30. 2004
    ..These results demonstrate that the engineered fusion hybrid vaccines that combine Th1 gene-modified tumor with DCs may be an attractive strategy for cancer immunotherapy...
  60. pmc Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering
    J Xiang
    Saskatoon Cancer Center, Department of Microbiology, University of Saskatchewan, Canada
    Immunology 78:574-81. 1993
    ..3 antibody, and the metal-binding capacity of the native metallothionein molecule. Therefore, the bifunctional hybrid protein B72.3MT-1 may be very useful in cancer imaging when labelled with radionuclides such as 99mTc...
  61. ncbi Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells
    Yongqing Liu
    Saskatoon Cancer Center, Department of Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W0, Canada
    Cancer Biother Radiopharm 17:11-8. 2002
    ..Our data indicate that the introduction of co-stimulatory CD40 ligand molecule will be useful as a new strategy of immunogene therapy against tumors...
  62. ncbi Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor
    Zhuang Chen
    Department of Oncology, Cancer Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Gene Ther 9:778-86. 2002
    ..Therefore, DCs genetically engineered to express both the tumor antigen and cytokines such as TNF-alpha as an immunoadjuvant are likely to represent a new direction in DC vaccine of cancer...
  63. doi Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity
    Yufeng Xie
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 25:21-8. 2010
    ..Therefore, TNF-alpha-expressing tumor cell-released EXO may represent a more effective EXO-based vaccine in the induction of antitumor immunity...
  64. ncbi Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity
    Zhenmin Ye
    Research Unit, Saskatchewan Cancer Agency, Departments of Oncology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 21:613-22. 2006
    ..Thus, our results may be important in designing DC-based cancer vaccines in the future...
  65. ncbi Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses
    Meiqing Shi
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 20:401-9. 2005
    ..Thus, SDF-1 has natural adjuvant activities that may augment antitumor responses through their effects on T-cells and thereby could be important in gene transfer immunotherapies for some cancers...
  66. ncbi Bidirectional membrane molecule transfer between dendritic and T cells
    Tianpei He
    Cancer Research Unit, Saskatchewan Cancer Agency, Departments of Oncology, University of Saskatchewan, Saskatoon, Sask, Canada
    Biochem Biophys Res Commun 359:202-8. 2007
    ..Taken together, this study demonstrated a novel phenomenon of bidirectional membrane molecule transfer between DCs and T cells...
  67. ncbi Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis
    Zhuang Chen
    Department of Oncology, Saskatoon Cancer Center, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada
    J Gene Med 7:506-17. 2005
    ..Hence, the strategy of combined irradiation and DC vaccine may be a novel approach for treating human malignancies and early metastasis...
  68. ncbi Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors
    Yongqing Liu
    Research Unit, Saskatchewan Cancer Agency, Departments of Microbiology, Immunology and Oncology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    J Gene Med 6:857-68. 2004
    ..We hypothesized that a combined immunotherapy including gene therapy and DC vaccine would have some advantages over each modality administered as a monotherapy...
  69. ncbi DNA microarray analysis of the gene expression profiles of naïve versus activated tumor-specific T cells
    Xueshu Zhang
    Department of Oncology, Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon Cancer Center, 20 Campus Drive CM200, Saskatoon, Saskatchewan, Canada S7N 0W0
    Life Sci 71:3005-17. 2002
    ....
  70. ncbi Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 21:146-54. 2006
    ..c. vaccination, the i.d. vaccination induced stronger antitumor immunity in the animal tumor model. Therefore, the i.d. EXO vaccination is superior to the s.c. one and should be considered when EXO-based vaccine is designed...
  71. ncbi Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion protein
    Meiqing Shi
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 20:260-6. 2005
    ..Taken together, these data suggest that microencapsulation of recombinant tumor cells secreting antibody/cytokine fusion protein might be an alternative approach in the treatment of cancers...
  72. ncbi CD8 alpha+, but not CD8 alpha-, dendritic cells tolerize Th2 responses via contact-dependent and -independent mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a mouse model of asthma
    John R Gordon
    Immunology Research Group, Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Immunol 175:1516-22. 2005
    ....
  73. doi Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses
    Xueshu Zhang
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, 20 Campus Dr, Saskatoon, Saskatchewan S7N 4H4, Canada
    J Leukoc Biol 88:393-403. 2010
    ....
  74. ncbi Advances in dendritic cell-based vaccine of cancer
    Xueshu Zhang
    Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 17:601-19. 2002
    ....
  75. ncbi Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma
    Yongqing Liu
    Research Unit, Saskatchewan Cancer Agency and Departments of Microbiology, Immunology and Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 0W0
    Cancer Gene Ther 12:122-32. 2005
    ..These findings could be beneficial for designing strategies of DCs vaccine and CD40L for anticancer immunotherapy...
  76. ncbi Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors
    Dajing Xia
    Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Res 16:241-59. 2006
    ..We underscore the fact that combined therapy may have some advantages in combating well-established tumors vis-a-vis either modality administered as a monotherapy...
  77. ncbi Genetically engineered myeloma cell vaccine
    Siguo Hao
    Sakatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada
    Methods Mol Med 113:235-44. 2005
    ..We also demonstrate that the engineered J558/CD40L tumor cells lose their tumorigenicity in syngeneic mice, and that the inoculation of J558/CD40L tumor cells further leads to protective immunity against wild-type J558 tumors...
  78. doi Intercellular trogocytosis plays an important role in modulation of immune responses
    Khawaja Ashfaque Ahmed
    Research Unit, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 5:261-9. 2008
    ....
  79. pmc Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation
    M Dean Chamberlain
    Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan S7N 4H4, Canada
    J Biol Chem 283:15861-8. 2008
    ..This critical new role for p85 in the regulation of Rab function suggests a novel role for p85 in controlling receptor signaling and trafficking through its effects on Rab GTPases...
  80. doi Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis
    Yufeng Xie
    Cell and Molecular Biology Institute, College of Medicine, Soochow University, Suzhou, China
    Cancer Biother Radiopharm 23:310-20. 2008
    ..Therefore, our results indicate its potent suppressive effect on human lung carcinoma cell line and warrant its further investigation for therapeutic application against human lung cancer...
  81. ncbi Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model
    Zhenmin Ye
    Cell and Molecular Biology Institute, College of Medicine, Soochow University, Suzhou, China
    Cancer Biother Radiopharm 21:225-34. 2006
    ..In mice bearing SMMC-7721 tumors, intratumoral injections of rAd- E1A significantly inhibited HCC growth. Therefore, the oncolytic adenovirus-mediated E1A gene therapy may be a useful therapeutic approach for HCC treatment...
  82. ncbi In vitro activation of CD8 interphotoreceptor retinoid-binding protein-specific T cells requires not only antigenic stimulation but also exogenous growth factors
    Yong Peng
    Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, KY 40202, USA
    J Immunol 176:5006-14. 2006
    ..As a result, cytokines, such as IL-7, supported the proliferation and survival of CD8 IRBP-specific T cells, while others had only a growth-promoting effect...
  83. ncbi Adenovirus-mediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis
    XiaoHua Wang
    Cell and Molecular Biology Institute, College of Medicine, Soochow University, Suzhou, China
    Cancer Biother Radiopharm 22:56-63. 2007
    ..Therefore, this study will provide a framework for future clinical applications of AdVGFP/IL-24 in HCC gene therapy...
  84. ncbi CpG-containing oligodeoxynucleotide 1826 converts the weak uveitogenic rat interphotoreceptor retinoid-binding protein peptide 1181-1191 into a strong uveitogen
    Hui Shao
    Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, KY 40202, USA
    J Immunol 171:4780-5. 2003
    ..Our results indicate that specific CpG-containing oligodeoxynucleotides may play an important role in the activation and expansion of autoreactive T cells in vivo, leading to autoimmune disease...
  85. ncbi Review: cancer immunotherapy by exosome-based vaccines
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency and Departments of Oncology, Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Cancer Biother Radiopharm 22:692-703. 2007
    ..This review will present the main biologic features of Dexo and Texo as cell-free cancer vaccines with emphasis on their immunostimulatory properties and their potential efficacy in cancer immunotherapy...